Change in the Chairmanship of the Board of Directors

Media Release
Zofingen, September 26, 2025

Ad hoc announcement pursuant to Art. 53 Listing Rules

Dr. Andreas Casutt (1963) has been a member of the Board of Directors of Siegfried Holding AG (SIX: SFZN) since 2010 and its Chairman since 2014. The attorney and partner at the Zurich law firm Niederer Kraft Frey AG has decided not to stand for re-election at the Annual General Meeting on April 16, 2026. 

Andreas Casutt, Chairman of the Board of Directors: “Even after 16 years on Siegfried’s Board of Directors, this decision is not an easy one for me. But the timing for a change in the chairmanship is right. Siegfried is best positioned today to continue its successful journey of growth.”  

Martin Schmid, Vice Chairman of the Board of Directors: “Andreas has significantly shaped our company over the past years. Under his leadership, Siegfried developed into a successful, global CDMO. His personal contribution to Siegfried’s ongoing success is substantial.”

The Board of Directors will propose to the 2026 Annual General Meeting that Dr. Beat Walti (1968) be elected the new Chairman of the Board of Directors. Beat Walti was elected to the Board of Directors of Siegfried Holding in 2022. The attorney chairs the Board of Trustees of the Ernst Göhner Foundation, Siegfried’s largest shareholder, holds board mandates at the Danish company DSV A/S and, as Chairman, at the Zurich-based trading company Rahn AG. In addition, he has been a member of the Swiss National Council since 2014, where he serves on the Economic Affairs and Taxation Committee.

Andreas Casutt: “Beat has many years of experience on the governing bodies of companies and foundations in Switzerland as well as internationally. In recent years, he has made significant contributions to Siegfried’s development as a member of our Board of Directors. Together with the Board and the Executive Committee, he will actively drive forward the expansion of our company’s market position in the years ahead.”

Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial

Pentixapharm Holding AG

/ Key word(s): Study/Research Update

Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial (news with additional features)

26.09.2025 / 08:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


 Achieves Key Milestone with CXCR4-based Radiotherapeutic

  • Favorable safety profile enables advancement of radiolabeled PentixaTher to fourth of five planned activity dose levels in investigator-initiated PENTILULA Phase 1/2 trial
  • Milestone marks important step for novel radiotherapeutic candidate in high unmet need indication with limited treatment options and poor prognosis

 Berlin, Germany, September 26, 2025 – Pentixapharm AG (Frankfurt Prime Standard: PTP), an advanced clinical-stage biotech, developing novel radiopharmaceuticals, today announced that its CXCR4-targeting radiolabeled candidate PentixaTher has advanced to the fourth dose level in the investigator-initiated PENTILULA Phase 1/2 study in acute myeloid leukemia (AML).

Based on favorable safety findings at the third dose level of 7.5 GBq, the investigator-initiated trial received approval from the independent Data Safety Monitoring Board (DSMB) to advance to the fourth of five planned dose levels at 10 GBq, underscoring PentixaTher’s tolerability to date. Importantly, this advancement not only reinforces the compound’s safety profile but also moves the study into a dose range with a higher likelihood for meaningful clinical efficacy. If favorable safety signals continue, the study is expected to escalate to a fifth and final dose level of 12.5 GBq.

AML is the most common acute leukemia in adults, with approximately 20,000 new cases annually in the U.S. and 17,000 new cases annually in Europe. Five-year survival rates range between approximately 32 and 37%, respectively.

“Advancing to higher dose levels marks a key step in validating the therapeutic potential and promise of PentixaTher,” said Dirk Pleimes, MD, CEO/CMO of Pentixapharm. “The encouraging results in this investor-led effort highlight the potential of CXCR4 as a powerful target for hematologic cancers and demonstrate the promise of radiopharmaceuticals to expand treatment options where medical need is greatest. The trial is expanding the clinical evidence base for CXCR4-targeted therapy to expand the boundaries of radiopharmaceuticals.”

Professor Françoise Kraeber-Bodéré, Nuclear Medicine Department, CHU Nantes, Principal Investigator, commented: “We are encouraged by the favorable safety profile observed to date, which has enabled us to move to higher activity dose levels. At dose level four, we are now entering a range considered of potentially higher effectiveness, and we look forward to evaluating the clinical impact in this high-need patient population.”

Professor Patrice Chevallier, Hematology Department, CHU Nantes added: “For patients with advanced AML, treatment options are limited, and prognosis in this often heavily pretreated population is poor. Reaching this dose level with an acceptable safety profile provides new hope that CXCR4-targeted radiopharmaceuticals could one day become a meaningful addition to the therapeutic landscape.”

  

About PentixaTher and the PENTILULA Phase 1/2 Study

Radiolabeled PentixaTher is a novel radiotherapeutic designed to selectively target the chemokine receptor CXCR4, a key player in the bone marrow microenvironment that is frequently overexpressed in aggressive hematological malignancies. The compound is labeled for the PENTILULA study with 177-lutetium, a clinically well-established isotope, enabling precise delivery of a targeted radiation payload. PentixaTher is currently being evaluated in the PENTILULA Phase 1/2 study (ClinicalTrials.gov ID: NCT06356922), initiated in November 2024. The multicenter, open-label, dose-escalation trial is led by an experienced investigator team at the University Hospital of Nantes and conducted at three additional clinical sites in France. It aims primarily to assess the safety and tolerability of PentixaTher, with secondary objectives including preliminary measures of clinical activity such as overall response rate, complete response rate, and overall survival. The study is supported by the French Ministry of Health.

 

About Pentixapharm

Pentixapharm is an advanced clinical-stage biotech expanding the boundaries of radiopharmaceuticals. Headquartered in Berlin, Germany, the company develops first-in-class ligand- and antibody-based radiopharmaceuticals designed to transform patient care across oncology and beyond. Its late-stage pipeline is anchored by CXCR4-targeted programs, including a Phase 3-ready diagnostic candidate for primary aldosteronism and pioneering therapeutic programs in a number of hematological and solid cancers. Furthermore, Pentixapharm is advancing a next-generation antibody platform targeting CD24, an emerging immune-escape marker over-expressed in multiple hard-to-treat cancers. Complemented by reliable isotope supply from Eckert & Ziegler, and a robust global clinical network, Pentixapharm is uniquely positioned to deliver innovative radiopharmaceuticals that address high unmet need, improve patient outcomes, and create significant growth opportunities in one of the fastest-growing areas of precision medicine.

 

About Nantes University Hospital

Nantes University Hospital (CHU de Nantes) is one of France’s leading healthcare institutions, recognized for its excellence in various medical specialties including cardiology, transplants, oncology, and neuroscience. The hospital is also a key player in medical research and innovation, conducting clinical trials and contributing to significant advancements in healthcare, in particular in nuclear medicine and hematology. [177Lu]Lu-PentixaTher is produced by ARRONAX, the hospital radiopharmacy unit (APUI), which is specially authorized for the preparation of the radiopharmaceutical investigational product.

 

Pentixapharm Investor and Media Contact

ir@pentixapharm.com


Additional features:

File: 20250925 – Pentixapharm PR IIT Nantes EN FINAL


26.09.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Pentixapharm Holding AG
Robert-Rössle-Straße 10
13125 Berlin
Germany
E-mail: info@pentixapharm.com
Internet: https://www.pentixapharm.com/
ISIN: DE000A40AEG0
WKN: A40AEG
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2203960

 
End of News EQS News Service

2203960  26.09.2025 CET/CEST

African Leaders Call for Bold, United Action to Tackle Global Health Crises and Sustain Malaria Progress

African Leaders Malaria Alliance (ALMA)

/ Key word(s): Miscellaneous

African Leaders Call for Bold, United Action to Tackle Global Health Crises and Sustain Malaria Progress

26.09.2025 / 13:15 CET/CEST

The issuer is solely responsible for the content of this announcement.


NEW YORK, United States of America, September 26, 2025/APO Group/ — African Heads of State and Government convened global leaders on Wednesday at a high-level event on the margins of the 80th United Nations General Assembly, sounding the alarm on escalating threats to global health security.

Convened under the theme “Uniting for Global Health Security”, the joint event brought together the Global Leaders Network for Women’s, Children’s and Adolescents’ Health, chaired by H.E. President Cyril Ramaphosa of South Africa, and the African Leaders Malaria Alliance (ALMA), chaired by President Advocate Duma Gideon Boko of Botswana. Discussions were moderated by the Rt Hon. Helen Clark, chair of the Partnership for Maternal, Newborn, and Child Health and former prime minister of New Zealand.

Amid growing concern over stagnating progress toward the Sustainable Development Goals for health, leaders called for urgent financial commitments, stronger partnerships, and bold, united action to protect the world’s most vulnerable, including women, children, and adolescents, from preventable diseases such as malaria.

“The fight against malaria is becoming increasingly complex,” said President Advocate Duma Gideon Boko. “Shrinking budgets, rising biological resistance, humanitarian crises, and the impact of climate change are all contributing towards creating a perfect storm of challenges,” he added.

Funding declines threaten progress

Recent years have seen a dramatic erosion of official development assistance (ODA) for health, with African leaders warning that life-saving programmes risk collapse in the absence of urgent and sustained financing. Between 2021 and 2025 alone, ODA for health in Africa declined by an estimated 70%, even as widening equity gaps, conflict, and displacement have expanded both needs and vulnerability.

H.E. President Cyril Ramaphosa highlighted the impact of these cuts, “essential programmes to eliminate malaria have been compromised. This leaves millions without care and erodes decades of progress that has been made so far.”

A successful Global Fund Replenishment is vital

Leaders reiterated support for the upcoming 8th replenishment of the Global Fund to Fight AIDS, Tuberculosis and Malaria, which aims to raise US$18 billion at its November 2025 conference. The Global Fund, established in 2002, has been central to progress against the three diseases, saving more than 70 million lives. Leaders stressed that the upcoming replenishment is critical, not only to sustain momentum but also to prevent a reversal of hard-won gains amid rising threats.

The ALMA chair issued a rallying call on the upcoming replenishment, “I call on all countries and donors to invest boldly in the Global Fund replenishment. If we all come together, we will save 23 million lives from malaria, AIDS and TB, while strengthening our health systems.”

Strengthening national ownership, innovative resource mobilisation and local manufacturing

While underscoring the importance of global solidarity, the African leaders noted that African ownership and accountability must be at the centre of the response, with H.E. President William Ruto of the Republic of Kenya saying “the future of Africa health financing lies in our own hands. Encouragingly, across the continent, change is already underway.”

Through initiatives like national End Malaria Councils and Funds, countries are embracing innovative financing approaches to expand the pool of resources for malaria, with 11 African countries already having mobilised over US$166 million, illustrating the power of multi-sectoral collaboration. 

At the same time, African leaders recommended tried and tested innovations, calling for the World Bank’s International Development Association (IDA) to set up a 2nd Malaria Booster Programme. The first malaria booster program (phase I and phase II) between 2005 and 2015 saw millions invested in malaria control and millions of cases prevented and lives saved. This vital programme helped “reinforce local health systems, such as community health workers, and enhance data systems and surveillance” said H.E. Muhammed B.S Jallow, vice president of the Republic of The Gambia.

With the recent IDA21 replenishment, there’s an opportunity to deliver a similar programme to address the challenges we face today, with the ALMA chair, President Advocate Duma Gideon Boko saying, “as ALMA, we are calling on the World Bank International Development Association to establish a second Malaria Booster Programme.” he said.

A push for national ownership was made by Dr Sania Nishtar, CEO of GAVI, who said “we strongly believe countries and not global health institutions should be at the centre of global health.” Dr Nishtar highlighted GAVI’s African Vaccine Manufacturing Accelerator which she said “promotes African self-reliance in vaccine manufacturing.” The GAVI CEO also shared that the vaccine alliance is “implementing the fastest vaccine rollout in Gavi’s 25-year history” with the introduction of malaria vaccines across 23 African countries, with early evidence showing a 13% drop in all-cause child mortality in vaccinated areas.

The need for public-private partnerships to deliver sustainable financing

Leaders called for the establishment of a Public-Private Partnership Health Accelerator to respond to declining traditional funding, with President Advocate Duma Gideon Boko encouraging fellow leaders to “think bigger and cast our net wider to mobilise even more resources to respond to the critical health challenges.”

This partnership will deliver new investments and drive progress toward universal health coverage. The accelerator is expected to leverage partnerships with the private sector, philanthropic foundations, high networth individuals and the diaspora, whilst reinforcing domestic commitments.

“We need a private-public partnership health accelerator that will drive whole-of-society progress towards the SDGs through sustainable high-value investments,” shared the ALMA chair.

This call for public private partnerships was endorsed by fellow leaders, with the vice president of the Republic of the Gambia saying these partnerships “can help us deliver sustainable financing at this critical moment and lead our continent to prosperity.”

The Big Push against Malaria

Earlier this year, the Africa Centre for Disease Control and Prevention (Africa CDC) unveiled a bold strategy to transform health financing across the continent amidst the volatile and ever-evolving global financing landscape. This momentum was amplified in Abuja with the launch of the “Big Push” to End Malaria in early September, placing malaria elimination at the heart of Africa’s health and development agenda. Building on this, African leaders at the UN General Assembly called for a paradigm shift in investments to sustain the fight against malaria and broader health challenges across the continent.

The joint event signalled renewed determination to confront overlapping crises with urgency, innovation, and unity, with H.E Dr Jean Kaseya, Director General of the Africa-Centres for Disease Control and Prevention, urging leaders to continue to turn these crises into opportunities to “start to raise sustainable financing, to build our own data system owned by the continent, to start to manufacture our own vaccines, medicines, and to build strong surveillance system. Now Africa is leading the world.”

As African countries moves towards greater ownership of our health systems and development agenda, Professor Senait Fisseha, a champion of sexual and reproductive health rights encouraged leaders to “to ensure it reflect our values, what we believe and is right, and is needed for our people” so that “we can create a continent in which every woman, every girl, every child can live to her fullest potential.”

“Together, let us rise to this moment. Let us prove that resilient health systems are the cornerstone of dignity, security and prosperity,” said H.E. President William Ruto of the Republic of Kenya at the conclusion of his remarks, echoing ALMA chair, President Advocate Duma Gideon Boko who said “we can make malaria elimination a reality. We can deliver a healthy tomorrow for women, babies, children and adolescents. The time to start is now.”

Distributed by APO Group on behalf of African Leaders Malaria Alliance (ALMA).

Download image: https://apo-opa.co/4gLjJ2s

Image Caption: L-R : H.E. President Advocate Duma Gideon Boko of Botswana, Chair of the African Leaders Malaria Alliance; H.E. President Cyril Ramaphosa of South Africa and Chair of the Global Leaders Network; H.E. President William Ruto of Kenya ;and the Rt. Hon. Helen Clark at the UNGA80 side-event on Global Health Security at the United Nations

 


26.09.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


2204474  26.09.2025 CET/CEST

DINAMIQS opens cGMP manufacturing facility for viral vectors

Media Release
Zofingen, September 29, 2025

DINAMIQS, a Siegfried company (SIX: SFZN), today inaugurated its state-of-the-art cGMP manufacturing facility for viral vectors — the first of its kind in Switzerland. The new facility enables end-to-end manufacturing of viral vector gene therapies, from molecule design to aseptic drug product filling. As part of this facility, new lab space has already been operational since Q3 2024. With this milestone, Siegfried strengthens its footprint in the rapidly growing cell and gene therapy market. To mark the inauguration, DINAMIQS also announced a strategic collaboration with SEAL Therapeutics to support the development and manufacturing of a gene therapy for a severe muscular dystrophy.

Marcel Imwinkelried, Chief Executive Officer Siegfried: “Since acquiring the startup in 2023, Siegfried’s ambition has been to bring DINAMIQS’ capabilities to commercial scale and establish it as a leading CDMO in the cell and gene therapy space. With the opening of the new manufacturing facility and growing customer demand, we are well on track to achieving this goal.”

Located in the Bio-Technopark in Zurich, DINAMIQS’ new 2,500m² cGMP facility brings R&D, clinical and commercial viral vector manufacturing under one roof, with production capacity up to 1,000L scale. Featuring a modular, segregated design and state-of-the-art closed, single-use technologies, it ensures strict containment, fast turnaround times, and full GMP compliance.

Martin Kessler, Chief Executive Officer DINAMIQS: “One of the biggest challenges that cell and gene therapy developers face today is scalability in process development and manufacturing. With the design of our facilities in Zurich, we enable our customers to get everything they need from one partner and one location. We offer lead optimization, R&D production and now also clinical and commercial supply – saving customers time and money when bringing their therapies to patients.”

In connection with the facility inauguration, DINAMIQS and SEAL Therapeutics announced the intention to enter a strategic collaboration. SEAL Therapeutics, a spin-off from the Biozentrum of the University of Basel, is developing an innovative gene therapy designed to address the functional defects that cause LAMA2 related muscular dystrophy, a severe childhood-onset disease characterized by progressive muscle loss and with no current treatment option. The research team led by Professor Dr. Markus Rüegg, Dr. Judith Reinhard and Dr. Thomas Meier will be supported by DINAMIQS experts to scale up production of their innovative gene therapy, enabling the transition from laboratory research toward potential patient treatment.

Markus Rüegg, Chief Executive Officer of SEAL Therapeutics: “To advance our viral vector-based gene therapy toward clinical application, we chose DINAMIQS for their specific expertise with the vector we require, their large-scale production capabilities, and their collaborative approach as a trusted Swiss-based partner.”

aap Implantate AG closes the first half of the year with sales of € 6.2 million; clinical trial nears positive conclusion

EQS-News: aap Implantate AG

/ Key word(s): Half Year Report/Half Year Results

aap Implantate AG closes the first half of the year with sales of € 6.2 million; clinical trial nears positive conclusion

16.09.2025 / 10:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

aap Implantate AG (“aap” or “Company”) informs:

  • Human Clinical Trial of Silver Antibacterial Technology Successfully Nears Completion and Opens Next Step to Regulatory Approval;
  • Existing customer business EMEA grows normalized by 11%, total aap 3% after excluding one-time UN order;
  • US tariff impact successfully mitigated;
  • APAC region strong growth driver

The first half of 2025 was marked by geopolitical uncertainties, fragile supply chains and new US tariffs. Despite these challenges, the company succeeded in strengthening its operating base and consistently driving forward strategic initiatives.

The introduction of US import tariffs (“Liberation Day”) at the beginning of April represented a turning point. Operational adjustments in supply chains and targeted price adjustments in the USA have reduced the impact of tariffs to a minimum.

Regionally, we were able to further expand our position in important markets:

  • EMEA: The EMEA region, which accounts for over 50% of total sales, maintained a solid baseline. Adjusted for one-off effects from the previous year, the region even recorded strong growth of 11% in existing customer business. Germany (+8% despite hospital structural reform), South Africa (+36%) and the MEA markets as a whole performed particularly well.
  • LATAM: The region stabilized in Q2 but was unable to close the Q1 gap. Brazil stands out with +37% growth, driven by the successful launch of the first LOQTEQ® foot systems after certification. Mexico and Colombia, on the other hand, fell short of expectations – Mexico due to delayed customer contract processes, Colombia due to structural challenges due to financing bottlenecks in the healthcare sector.
  • APAC: Successful market development continues. With initial activities in the new markets of South Korea and Taiwan as well as strong growth in Thailand (+26%), the customer base was significantly expanded. The region achieved an impressive growth of 82% and promises further growth in the future.
  • USA: The strategic transformation was initially slower than expected, but the implemented strategies and intensified customer activities are now starting to take effect. In June, monthly sales of over USD 0.3 million were achieved – a clear signal that the reorganization and targeted customer relationships initiated in 2023 are bearing fruit.

 

Revenue Q2/HY 2025/2024

Revenue in EUR thousand Q2/2025 Q2/2024 Change
EMEA (= Europe, Middle East, Africa)
North America
LATAM (= Latin America)
APAC (= Asia-Pacific)
1.569
642
642
299
1.907
683
639
102
-18%
-6%
+1%
+>100%
Turnover 3.152 3.330 -5%

 

Revenue in EUR thousand H1/2025 H1/2024 Change
EMEA (= Europe, Middle East, Africa)
North America
LATAM (= Latin America)
APAC (= Asia-Pacific)
3.271
1.290
1.221
454
3.334
1.429
1.427
250
-2%
-10%
-14%
+82%
Turnover 6.236 6.440 -3%

With regard to the USA, the success story of the strategic realignment is somewhat clearer when viewed after adjusting for currency effects. The operating decline decreased continuously from -9% in the first half of the year to only -1% in the second quarter – clear evidence that the transformation initiated in 2023 is taking effect.

Revenue in USD (million) Q2/2025 Q2/2024 Change
North America 0,7 0,7 -1%

 

Revenue in USD (million) H1/2025 H1/2024 Change
North America 1,4 1,5 -9%

 

Due to the continuously growing customer base and simultaneous investments by existing customers in the aap portfolio, the company plans to increase orders on the revenue side for the second half of 2025 compared to the first 6 months.

Key financial figures for the first half of 2025 aap Group (unaudited)

In EUR million, rounded 01.01.-30.06.2025 01.01.-30.06.2024 Change
Turnover 6,2 6,4 -0,2
Gross margin* 5,2 5,2 -0,1
Other operating income 0,6 0,9 -0,3
Personnel costs -2,9 -3,2 0,3
Operating costs -3,2 -3,1 -0,1
EBITDA -0,3 -0,0 -0,2
Operating profit (EBIT) -1,0 -0,8 -0,2
Net Revenue -1,0 -0,9 -0,1
       
Margins in %      
Gross margin* 85% 87%  
EBITDA -5% -0%  
Operating profit (EBIT) -16% -12%  

*(Gross margin = sales +/- inventory changes – material expenses / sales revenues)

Key financial figures for the first half of 2025 aap by segment (unaudited)

  30.06.2025 30.06.2024
Figures in EUR thousand TraumaLOQTEQ® Silver Total TraumaLOQTEQ® Silver Total
Earnings before interest, taxes,
depreciation and amortization (EBITDA)
56 -348 -292 335 -382 -46

The measures taken at the end of 2023, ongoing optimizations and the organic increase in sales are showing financial success in the first half of the year. aap achieved an almost break-even result in consolidated earnings at EBITDA level, while the positive trend was confirmed in the trauma business at EBITDA level. The EBITDA difference compared to the previous year is primarily related to the deviation in sales and the reduced other operating income.

Cashflow (unaudited)

In EUR million, rounded 01.01.-30.06.2025 01.01.-30.06.2024 Change
Cash flow operating -0,2 -1,0 0,8
Cash Flow Investment -0,3 -0,0 -0,3
Cash Flow Financing -1,0 0,5 -1,5
       
  30.06.2025 31.12.2024  
Cash and cash equivalents 0,6 2,1 -1,5
Net position 0,4 0,4  

The significant improvement in operating cash flow was mainly due to a stable gross margin of over 85% (despite inflation-related increases in material prices), lower personnel costs compared to the previous year (mainly reduction in vacation provisions), and an improved margin and cost situation in the United States (higher margins with stable fixed costs).

 

Financing
In July 2025, the company was able to conclude a lease-sale back agreement with NordLeasing company to secure liquidity. The company thus received EUR 725 thousand. The leasing contract has a term of four years.

 

Operational activities

Bottlenecks at our notified body delayed the expected MDR approvals for plates and screws, which had a negative impact on sales planning and production. On the other hand, the MDR approvals for products of classes Im, Ir and IIa were successfully completed, which confirms the high quality of our submitted documents. These successes make us confident that the remaining registrations will follow soon.

Regarding the human clinical trial with antibacterial implants, we refer to the most recent press release of September 09, 2025. The Internet address contained in the press release regarding the guideline of the study has changed due to a name change of the funding agency. It has been updated in the following text.

The clinical trial is funded by the German Federal Ministry of Education and Research (“BMBF”). The grant granted to the company (funding codes 13GW0313A+B, 13GW0449A+B) is part of the BMBF’s field of action “Healthcare Economics in the Health Research Framework Program” (= funding body). According to the BMBF, funding is provided for projects on the topic of “Transferring medical technology solutions into patient care – proving clinical evidence without delay”. For further information, please refer to the corresponding guideline on the BMBF website: https://www.bmftr.bund.de/SharedDocs/Bekanntmachungen/DE/2024/07/2024-07-29-Bekanntmachung-L%c3%b6sungen.html.

Outlook for the second half of 2025

For the second half of 2025, in addition to the forecasts already formulated in the 2024 annual financial statements, the focus is on several important milestones: the stabilization of liquidity for ongoing investments, the completion of the human clinical trial, the preparation of the study report by the end of the year for our antibacterial implant technology and the completion of the MDR approval work. At the beginning of September, we had already very successfully passed the MDR recertification of the company and the US FDA inspection.

 

On the revenue side, the Management Board plans to increase sales for the second half of the year compared to the first six months and maintains its forecast for the year as a whole.

 

——————————————————————————————————————————————-

aap Implantate AG (ISIN DE0005066609) – General Standard/Regulated Market – All German Stock Exchanges –

 

 

About aap Implantate AG

 aap Implantate AG is a global medical technology company headquartered in Berlin, Germany. The company develops and markets products for traumatology. In addition to the innovative anatomical plate system LOQTEQ®, the IP-protected portfolio includes a wide range of perforated screws. In addition, aap Implantate AG has an innovative pipeline with promising development projects, such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical and not yet adequately solved problems in traumatology.  In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups and affiliated clinics, while on an international level, it primarily uses a broad network of distributors in around 25 countries. In the USA, the company and its subsidiary aap Implants Inc. rely on a distribution agent and selective direct sales strategy. The shares of aap Implantate AG are listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website at www.aap.de.

 

There may be technical rounding differences in the figures presented in this press release, which do not affect the overall statement.

 

Forward-Looking Statements

This release may contain forward-looking statements based on the current expectations, assumptions and forecasts of the Management Board and information currently available to it. The forward-looking statements are not to be understood as guarantees of future developments and results referred to therein. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial condition, development or performance of the Company to differ materially from the estimates given herein. These factors also include those described by aap in published reports. Forward-looking statements therefore speak only as of the date on which they are made. We undertake no obligation to update the forward-looking statements made in this release or to conform them to future events or developments.

 

If you have any questions, please contact: aap Implantate AG; Rubino Di Girolamo; Chairman of the Board of Directors/CEO; Lorenzweg 5; 12099 Berlin

Phone: +49 (0)30 75019 – 141; Fax: +49 (0)30 75019 – 170; Email: r.digirolamo@aap.de

 


16.09.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Newron presents H1 2025 results and provides business update

EQS-News: Newron Pharmaceuticals S.p.A.

/ Key word(s): Half Year Results

Newron presents H1 2025 results and provides business update

16.09.2025 / 07:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

Newron presents H1 2025 results and provides business update 

Milan, Italy, September 16, 2025, 07:00 am CEST – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the half-year ended June 30, 2025, and provided a business update for 2025 and beyond.

Highlights H1 2025:

Evenamide

Clinical trials:

  • In May, the Company announced regulatory approval for its pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS). The program consists of two pivotal studies:
    • ENIGMA-TRS 1, an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients. Following a successful screening period, patient enrolment began post-period, in August 2025, with 12-week study results expected in Q4 2026
    • ENIGMA-TRS 2, approved by the US Food and Drug Administration, to be performed at centers in the US and selected additional countries. This 12-week, double-blind, placebo-controlled Phase III study in at least 400 patients is expected to start by October 2025

Strategic licensing and partnerships:

  • In January, the Company announced a licensing agreement with Myung In Pharm to develop, manufacture and commercialize evenamide in South Korea
    • Under the terms of the agreement, Myung In Pharm will contribute 10% of the total patient population to be enrolled into Newron’s upcoming Phase III ENIGMA-TRS 1 study and will cover the costs related to this population
  • Following the execution (in December 2024) of the licensing agreement with EA Pharma, a subsidiary of Eisai, to develop, manufacture and commercialize evenamide in Japan and other designated Asian territories, Newron in the reporting period received the upfront payment of EUR 44 million and invoiced the first milestone achievement
  • Newron continues to actively explore additional partnership opportunities for the global development and commercialization of evenamide in other territories

Industry engagement and scientific exchange:

  • In January, evenamide’s exceptional results in study 014/015 and study 008A were published in the peer reviewed International Journal of Neuropsychopharmacology
  • Post-period, in August 2025, new preclinical data from researchers at the University of Pittsburgh was published in the peer-reviewed journal Neuropsychopharmacology. The research suggests that evenamide ameliorates schizophrenia-related dysfunction, targeting the key site of schizophrenia pathology in the hippocampus, and so could be an ideal therapeutic agent for the treatment of schizophrenia

Corporate

  • In April, Dr. Chris Martin was elected as the Chairman of Newron’s Board of Directors, succeeding Dr. Ulrich Köstlin who served as Chairman of the Company from 2013

Stefan Weber, CEO of Newron, commented: “Since the beginning of the year, Newron has continued to make exciting progress in the development of our novel drug candidate evenamide. Most notably, we announced the approval of our pivotal ENIGMA-TRS Phase III development program evaluating evenamide as an add-on therapy in patients with treatment-resistant schizophrenia (TRS) and recently we began enrolling patients into the first study from the program, ENIGMA-TRS 1. We’re delighted to have achieved this crucial milestone on evenamide’s clinical development journey and continue to believe that this new chemical entity has blockbuster potential and could bring enormous benefits to patients who are insufficiently served by the treatments currently available.”

Evenamide – advancing schizophrenia treatment

In January, Newron announced its licensing agreement with Myung In Pharm to develop, manufacture and commercialize evenamide as an add-on therapy for TRS and poorly responding patients with schizophrenia in South Korea. Under the terms of the agreement, Myung In Pharm, besides the usual financial terms for such agreement, will contribute 10% of the total patient population to be enrolled into Newron’s pivotal ENIGMA-TRS 1 clinical trial and cover the costs related to this population.

There has also been strong progress from EA Pharma, who Newron has entered into a license agreement with to develop, manufacture and commercialize evenamide in Japan and other designated Asian territories. EA Pharma expects to initiate its clinical development program for evenamide in Japan. Also, the first milestone under the license agreement became due and was invoiced in the reporting period.

In May, Newron announced the regulatory approval of its pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with TRS. More than one third of schizophrenia patients suffer from TRS and are not responding to the existing second-generation antipsychotics on the market. Consequently, these patients are in great need of the development and approval of new therapeutic treatments. If approved, evenamide would be the first medication added to existing antipsychotics that improves the symptoms of TRS.

The ENIGMA-TRS Phase III development program consists of two pivotal studies, ENIGMA-TRS 1 and ENIGMA-TRS 2:

  • ENIGMA-TRS 1 is an international, 52-week, randomized, double-blind, placebo-controlled Phase III study evaluating the efficacy, tolerability, and safety of the 15mg BID and 30mg BID therapeutic doses of evenamide as an add-on treatment to current antipsychotics, compared to placebo. Patients on second-generation antipsychotics (SGAs), including clozapine, will meet Treatment Response and Resistance Psychosis (TRRIP) international consensus criteria for TRS. The study will enroll at least 600 patients at study centers in Europe, Asia, Latin America and Canada.
  • The primary assessment of efficacy and safety of ENIGMA-TRS 1 will be performed 12 weeks after randomization to treatment. Following this initial period, the study will continue double-blind and placebo-controlled until the 52-week time point. The primary efficacy endpoint of the trial will be the change from baseline in the Positive and Negative Syndrome Scale (PANSS) scores at 12 weeks. Newron expects to announce 12-week results from the study in Q4 2026.
  • ENIGMA-TRS 1 is actively screening across all target continents. Post-period, in August 2025, Newron announced that the first patients have been successfully enrolled following the completion of a 42-day screening period. Newron’s partner Myung In Pharm has also received the necessary approvals in South Korea to move towards enrolling patients in this region.
  • ENIGMA-TRS 2, the second study in Newron’s pivotal Phase III development program, has been approved by the US Food and Drug Administration (FDA), and will be performed at centers in the US and selected additional countries. ENIGMA-TRS 2 will include at least 400 patients in a 12-week, randomized, double-blind, placebo-controlled Phase III study, designed to evaluate the efficacy, tolerability, and safety of the 15mg BID dose of evenamide as an add-on treatment to current antipsychotics, compared to placebo.
  • Patients will undergo the same screening as the ENIGMA-TRS 1 trial. The efficacy and safety analysis will be performed at the 12-week point following successful completion of the study. US investigational centers are expected to initiate the study by October 2025.

Shortly after the reporting period, in August 2025, new preclinical data from Dr. Anthony Grace and other researchers at the University of Pittsburgh was published in the peer-reviewed journal Neuropsychopharmacology. The data suggests that evenamide ameliorates schizophrenia-related dysfunction, and for the first time demonstrates that evenamide targets the key site of schizophrenia pathology in the hippocampus. Using the neurodevelopmental MAM model of schizophrenia, researchers demonstrated that evenamide could offer a novel therapeutic strategy capable of addressing the positive, cognitive, and negative symptoms of schizophrenia, a key advantage over existing antipsychotic drugs which only target positive symptoms.  Importantly, time-course analysis indicates effects of a single dose of evenamide last long after elimination of drug, suggesting effect on neuronal plasticity. These findings help explain the robust and sustained symptom improvements observed in Newron’s Phase II and Phase III studies in patients with chronic schizophrenia, reinforcing evenamide’s potential as a transformative therapy for treatment-resistant and poorly responding patients, and offering a promising alternative to traditional dopamine D2-based antipsychotics.

Xadago®/safinamide – Parkinson’s disease

In partnership with Zambon and Meiji Seika, Newron continues to develop and market its product, Xadago®/safinamide.

Corporate

At the Annual General Meeting 2025, Dr. Chris Martin was elected as the new Chairman of the Board following his nomination by the Company. Chris Martin took over from Dr. Ulrich Köstlin, who served as Chairman of Newron’s Board since 2013. Dr. Martin is a recognized leader in the biopharma industry who has taken therapeutic technology from the lab bench through to regulatory approval and global market sales. He co-founded ADC Therapeutics in 2012 and served as its CEO from its inception until 2022, growing the company from a private biotech start-up to a New York Stock Exchange listed leader in the field of antibody-drug conjugates with products marketed worldwide. Chris Martin also co-founded and was the CEO of Spirogen, an innovator of antibody-drug conjugate payload technology, which was subsequently sold to AstraZeneca for a total of up to $440 million.

Outlook

Following the approval of the pivotal Phase III ENIGMA-TRS program for evenamide and the subsequent initiation of the ENIGMA-TRS 1 study, Newron’s key focus for the coming months is on progressing this study and initiating ENIGMA-TRS 2, initially in the US study centers.

In addition to its licensing agreements with Myung In Pharm and EA Pharma, Newron continues to be supported by one of world’s leading full-service investment banking and capital markets firms in a structured process to secure the most attractive, value creating transactions for the Company’s shareholders.

Furthermore, to comprehensively protect the future value of evenamide for shareholders and new investors, Newron is currently in the process of filing additional patent applications to further extend the Intellectual Property protection around evenamide as a novel treatment for schizophrenia. Additionally, the existing patent applications pertaining to evenamide continue to be granted within the European Union and the US.

Newron CEO Stefan Weber concluded: “We are very excited about our continued achievements, and we are one step closer to potentially bringing enormous benefits to schizophrenia patients who are insufficiently served by the treatments currently available. The financial position of our Company remains strong – Newron’s total available cash resources are expected to fund our planned development programs and operations well towards the end of the year 2026.”

Financial Summary (IFRS) H1 2025 and 2024:

In thousand EUR (except per share information)

  H1 2025 H1 2024
Licence income/Royalties/Other income 11,898 3,407
Research and development expenses (6,081) (6,453)
General and administrative expenses (4,423) (4,579)
Net loss (73) (9,557)
Loss per share (0.00) (0.51)
Cash generated/(used) in operating activities 33,353 (8,828)
  As of June 30, 2025 As of December 31, 2024
Cash and Other current financial assets 43,195 9,826
Total assets 61,394 63,908

Newron’s Half-Year Report 2025 is available for download on the Company’s website at: www.newron.com/investors/reports-and-presentation/year/2025

About Newron Pharmaceuticals

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on developing novel therapies for patients with diseases of the central and peripheral nervous system.

Headquartered in Bresso, near Milan, Italy, Newron is advancing its lead compound, evenamide, a first-in-class glutamate modulator, which has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently in Phase III development and clinical trial results to date demonstrate the benefits of this drug candidate in the TRS patient population, with significant improvements across key efficacy measures increasing over time, as well as a favourable safety profile, which is uncommon for available antipsychotic medications.

Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea.

Newron has a proven track record in bringing CNS therapies to market. Its Parkinson’s disease treatment, Xadago® (safinamide), is approved in over 20 markets, including the USA, UK, EU, Switzerland, and Japan, and commercialized in partnerships with Zambon and Meiji Seika.

For more information, please visit: www.newron.com 

For more information, please contact:

Newron
Stefan Weber – CEO; +39 02 6103 46 26, pr@newron.com

UK/Europe
Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting; +44 20 3727 1000, SCnewron@fticonsulting.com  

Switzerland
Valentin Handschin, IRF; +41 43 244 81 54, handschin@irf-reputation.ch

Germany/Europe
Anne Hennecke / Maximilian Schur, MC Services; +49 211 52925227, newron@mc-services.eu

USA
Paul Sagan, LaVoieHealthScience; +1 617 865 0041, psagan@lavoiehealthscience.com
 

Important Notices
This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron’s strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron’s research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.


16.09.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


MPH Health Care AG publishes figures for the first half-year of 2025: Equity (NAV) amounts to EUR 205.1 million, which corresponds to EUR 47.91 per share. The equity ratio fell slightly to 93.7%

EQS-News: MPH Health Care AG

/ Key word(s): Half Year Results/Quarter Results

MPH Health Care AG publishes figures for the first half-year of 2025: Equity (NAV) amounts to EUR 205.1 million, which corresponds to EUR 47.91 per share. The equity ratio fell slightly to 93.7%

16.09.2025 / 08:30 CET/CEST

The issuer is solely responsible for the content of this announcement.

MPH Health Care AG publishes figures for the first half-year of 2025:

 Equity (net asset value) amounts to EUR 205.1 million, which corresponds to EUR 47.91 per share. The equity ratio fell slightly to 93.7% (31 December 2024: 95.5%)

Berlin, 16th September 2025 – MPH Health Care AG (ISIN: DE000A289V03) announces the preliminary IFRS consolidated results for the first half-year of 2025. Accordingly, equity decreased by 26% from EUR 277.9 million as of 31 December 2024 to EUR 205.1 million as of 30 June 2025. The net asset value (NAV) per share fell from EUR 64.90 (31 December 2024) to EUR 47.91 as of 30 June 2025.

The IFRS result for the period decreased from EUR 74.5 million as of 30 June 2024 to EUR -72.7 million as of 30 June 2025. This result is due to the accounting valuations of the investments as at the reporting date, which do not affect cash flow. MPH AG is an investment company whose investments are reported as financial assets under the balance sheet item ‘Financial investments’ and are measured at fair value through profit or loss on the balance sheet date.

The equity ratio fell slightly from 95.5% to 93.7% and remains at a very high level.

The financial position has improved compared to the previous year. From 1 January to 30 June 2025, an operating cash flow of kEUR 1,016 was generated (previous year: kEUR -895) and a net cash flow of kEUR 261 (previous year: kEUR -2,781).

The fair value losses are mainly due to the sharp decline in the share price of our listed investment CR Energy AG, which unexpectedly filed for (preliminary) insolvency proceedings with the competent local court in Potsdam in June 2025. The price of CR shares fell from EUR 4.78 on 31 December 2024 to EUR 0.54 on 30 June 2025.

The M1 Kliniken AG investment continued its growth trajectory in the first half of 2025, once again increasing both revenue and earnings. IFRS consolidated revenue in the first half of 2025 amounted to EUR 183.5 million, compared with EUR 167.7 million in the first half of 2024. This represents an increase of 9.4%. The Group EBIT margin increased by approximately 14% to 9.8% in the first half of 2025 (same period last year: 8.6%). Operating profit (EBIT) increased to EUR 18.0 million (previous year: EUR 14.5 million). Net profit (before minority interests) as of 30 June 2025 rose by around 19% to EUR 12.5 million.

M1 Kliniken AG continues to grow and aims to increase revenue in the high-margin beauty segment to EUR 200–300 million per year by 2029, with a sustainable EBIT margin of at least 20%. With a dividend payment of EUR 0.50 per share, M1 Kliniken AG is reaffirming its distribution policy.

At this year’s Annual General Meeting of MPH Health Care AG on 17 July 2025, it was resolved to distribute a dividend of EUR 1.20 per dividend-bearing share, as in the previous year, and to carry forward the remaining amount of the 2024 net profit of EUR 72.5 million to new account.

The half-yearly report of MPH Health Care AG is available for download under Financial Reports – MPH Health Care AG.

About MPH Health Care AG:

MPH Health Care AG is an investment company with a strategic focus on the acquisition, development and sale of companies and company shares, particularly in growth segments of the healthcare market. This includes both insurance-financed and privately financed segments. However, MPH also aims to exploit potential opportunities in high-growth and high-yield sectors outside the healthcare market.

 

Contact:
Patrick Brenske, Management Board
Corporate Communications
E-Mail: ir@mph-ag.de


16.09.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Gerresheimer delivers solid results in the financial year 2024 despite market headwinds

EQS-News: Gerresheimer AG

/ Key word(s): Annual Results

Gerresheimer delivers solid results in the financial year 2024 despite market headwinds

26.02.2025 / 07:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

Gerresheimer delivers solid results in the financial year 2024 despite market headwinds

  • Organic growth: revenue +2.9%, adjusted EBITDA +4.1%
  • Destocking in vial business partially offset by strong growth in medical devices
  • Growth strategy execution: capacity expansions and higher revenue share from solutions for biologics
  • Bormioli Pharma to boost revenues and adjusted EBITDA from 2025 with integration well underway

Duesseldorf, February 26, 2025: Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, achieved solid results and continued to grow profitably in financial year 2024. Revenues reached EUR 2,035.9m (2023: EUR 1,990.5m), while adjusted EBITDA amounted to EUR 419.4m (2023: EUR 404.5m). Organic sales grew by +2.9% and adjusted EBITDA by +4.1%. The adjusted EBITDA margin improved to 20.6% (2023: 20.3%). The Plastics & Devices Division benefited from the strong growth in medical devices, partially offsetting the destocking effects in the vial business in the Primary Packaging Glass Division. The first signs of a market recovery in the vial business were seen in the fourth quarter of 2024, but destocking effects at customers weighed on the results of the Primary Packaging Glass Division in the full year 2024. Bormioli Pharma will contribute significantly to the Group’s revenues and Adjusted EBITDA from the financial year 2025 while the integration into the Gerresheimer Group is well underway. For the financial year 2025, the combined group of companies including Bormioli Pharma now expects organic revenue growth of 3-5% compared to combined pro forma figures of the previous year. The adjusted EBITDA margin is expected to improve further to around 22%. The Group anticipates profitable growth in the coming years through the consistent execution of its growth strategy.

“2024 was characterized by temporary market effects in one of our submarkets,” says
Dietmar Siemssen, CEO of Gerresheimer AG. “Our long-term growth prospects remain positive. We are growing strongly in systems and solutions for large-molecule biologics for which we are systematically expanding our production capacities. With the acquisition of Bormioli Pharma, we have expanded our product portfolio and created the basis for new, integrated high value plastic solutions. All of this will help us to continue our profitable growth in the coming years.”

Plastics & Devices: Significant growth with improved margin
The Plastics & Devices Division generated revenue of EUR 1,141.3m in the financial year 2024 (2023: EUR 1,065.1m). Organic revenue growth amounted to 8.0%. The main driver of this positive development was the strong demand for drug delivery systems. Demand for plastic containment solutions also remained at a high level. Adjusted EBITDA reached EUR 293.7m (2023: EUR 270.0m). Adjusted EBITDA grew organically by 8.8% compared to the same period of the previous year. The division also increased its Adjusted EBITDA margin to 25.7% (2023: 25.3%). The positive development was driven by a higher proportion of specially tailored solutions for biologics, including GLP-1 products for the treatment of obesity.

Primary Packaging Glass: Destocking effects moderating
The first signs of a market recovery became visible in the fourth quarter of 2024, but business development in the Primary Packaging Glass Division in the financial year 2024 was still significantly influenced by destocking effects at pharmaceutical customers, particularly in the area of standard vials (“bulk vials”). Sales revenues reached EUR 898.6 million (2023: EUR 927.3 million). In organic terms, they were thus 2.6% below the same period of the previous year. Adjusted EBITDA amounted to EUR 177.2m (2023: EUR 182.5m). In organic terms, adjusted EBITDA was 2.4% below the prior-year period. The adjusted EBITDA margin remained stable at 19.7% (2023: 19.7%). Gerresheimer expects that destocking effects for standard vials will continue to moderate in the course of 2025.

High dividend continuity – dividend proposal of EUR 1.25
Gerresheimer’s adjusted net income increased to EUR 164.6m in the financial year 2024 (2023: EUR 158.0m). Adjusted EPS at constant currency rose to EUR 4.67 (2023: EUR 4.62). The Executive Board and Supervisory Board will therefore once again propose a dividend of EUR 1.25 per share for the financial year 2024 at the Annual General Meeting. This corresponds to a payout ratio of 26.0%. The proposed dividend is therefore within the payout range of 20% to 30%.

Bormioli Pharma – new category of high value plastic solutions through system integration

At the beginning of December 2024, Gerresheimer successfully completed the acquisition of the Bormioli Pharma Group. Bormioli Pharma will thus be fully consolidated in the Gerresheimer Group from the financial year 2025. The integration of the company is one of Gerresheimer’s focus topics of the financial year 2025 in order to seize the opportunities of the expanded product portfolio and the possibilities of system integration for new high-value plastic solutions. The acquisition also enables the formation of a stand-alone global moulded glass powerhouse.

Profitable growth expected in subsequent years

In view of the strong growth in systems and solutions for biologics, the successful execution of the growth projects in this area and the expanded portfolio of high value solutions, Gerresheimer expects profitable growth in the coming years.

Guidance for FY 2025 (organic)

  • Revenue growth: 3-5%
  • Adjusted EBITDA margin: around 22%
  • Adjusted EPS growth: high single-digit percentage range

Mid-term guidance (organic)

  • Revenue growth: 8-10 % CAGR
  • Adjusted EBITDA margin: 23 – 25%
  • Adjusted EPS growth: ≥ 10% CAGR

The Annual Report 2024 is available on the Gerresheimer website here:

https://www.gerresheimer.com/en/company/investor-relations/reports

 

About Gerresheimer
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets.  Together with Bormioli Pharma 2024, the Group generated revenues of around EUR 2.4bn and currently employs around 13,400 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
www.gerresheimer.com

Contact Gerresheimer AG

Media  
Jutta Lorberg
Head of Corporate Communication
T +49 211 6181 264

jutta.lorberg@gerresheimer.com
Marion Stolzenwald
Senior Manager Corporate Communication
T +49 172 2424185

marion.stolzenwald@gerresheimer.com
Investor Relations  
Guido Pickert
Vice President Investor Relations

T +49 152 900 14145
gerresheimer.ir@gerresheimer.com

 
Thomas Rosenke
Senior Manager Investor Relations
T: +49 211 6181-187
gerresheimer.ir@gerresheimer.com


26.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this

Straumann Group announces Executive Management Board changes

Straumann Holding AG

/ Key word(s): Personnel

Straumann Group announces Executive Management Board changes

26.02.2025 / 07:00 CET/CEST

Basel, February 26, 2025: Today the Straumann Group announces two executive management board changes. The first one is that Yang Xu, Chief Financial Officer(CFO), has decided to leave the Straumann Group as of May 2025 to pursue opportunities outside the company. The search for a new CFO has been started and succession will be announced shortly.

The second announcement is that Grant Bester will assume commercial responsibility for the North America region and join the Executive Management Board in April 2025. His onboarding will begin at the Straumann Group headquarters, alongside Guillaume Daniellot. In parallel, we would like to thank Aurelio Sahagun for his dedication and leadership over the past four years during which he guided the North America region through a challenging period. He will support a professional transition until the end of March, and then will pursue opportunities outside the company.

Guillaume Daniellot, Chief Executive Officer, said: “I would like to personally thank Yang Xu for her unwavering dedication in leading our finance organization. While I am sad to see her move on, I sincerely wish her all the best in her future endeavors. In addition, I’m very excited to soon have Grant on board. He is an exceptional, passionate leader with an impressive, strong, high-performance mindset and will further drive the success of our second-largest region, North America. I would also like to sincerely thank Aurelio for everything he has done for the company and wish him all the best for the future.“

Grant Bester to serve as Executive Commercial leader for North America 

As Executive Commercial Leader for North America, Grant Bester will assume commercial responsibility over the North America region and become a Member of the Executive Management Board. Grant joins from the Polaris Group where he was Vice President International for Polaris and then for Indian Motorcycle, overseeing the business internationally. Before that, Grant worked for Stryker, a global medical technology company, as Vice president and Chief Marketing officer. During his tenure, he was responsible for the orthopedics, trauma, and spinal business across multiple regions. Grant had a varied career, not only in corporate roles but has also been involved in entrepreneurial ventures, running his own business in professional imaging.

Born in 1971, Grant is South African-born, studied business management at the University of Johannesburg and furthered his executive education through programs at the Manchester Business School and Harvard University.

About Straumann Group

The Straumann Group (SIX: STMN) is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Anthogyr, ClearCorrect, Medentika, Neodent, NUVO, Straumann and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials and digital solutions for use in tooth correction, replacement and restoration or to prevent tooth loss. Headquartered in Basel, Switzerland, the Group currently employs close to 12’000 people worldwide. Its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland.
Phone: +41 (0)61 965 11 11
Homepage: www.straumann-group.com

Contacts:  

Corporate Communication

Silvia Dobry: +41 (0)61 965 15 62

Frank Keidel +41 (0)79 530 71 84

corporate.communication@straumann.com

Investor Relations

Marcel Kellerhals: +41 (0)61 965 17 51

Derya Güzel +41 (0)61 965 18 76

investor.relations@straumann.com

Disclaimer

This press release contains forward-looking statements, including statements regarding the beliefs, expectations and assumptions of future results, performance or achievements of Straumann Group, that are based upon information available to Straumann Group as of the date such statements are made. Forward-looking statements are neither historical facts nor assurances of future performance. They may, but need not, be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “believe,” “project,” “estimate,” “expect,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods or events. Such forward-looking statements reflect the views, beliefs, assumptions and expectations of Straumann Group or its management at the time the statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may be outside of Straumann Group’s control. Such known and unknown risks, uncertainties and other factors underlying forward-looking statements may cause the actual results, performance or achievements of the Group to differ materially from those expressed or implied in this document. Accordingly, you should not rely on any forward-looking statements contained in this press release. Important factors that could cause the Group’s expectations regarding future results, performance or achievements to differ materially from those expressed in a forward-looking statement include, but are not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann Group’s control. Should one or more of these risks, uncertainties or other factors materialize or should underlying views, beliefs, assumptions or expectations prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann Group is providing the information in this release as of the date it is issued and does not undertake any obligation to update any statements as a result of new information, future events or otherwise.This release constitutes neither an offer to sell nor a solicitation to buy any securities.

 


End of Media Release


show this

Affluent Medical appoints Liane Teplitsky – a senior executive in the medical device industry as a new member of the Board of Directors

EQS-News: Affluent Medical SA

/ Key word(s): Personnel

Affluent Medical appoints Liane Teplitsky – a senior executive in the medical device industry as a new member of the Board of Directors

25.02.2025 / 17:45 CET/CEST

The issuer is solely responsible for the content of this announcement.

 Affluent Medical appoints Liane Teplitsky – a senior executive in the medical device industry as a new member of the Board of Directors

Aix-en-Provence, February 25, 2025 – 5:45 p.m. CET – Affluent Medical (ISIN: FR0013333077 – Ticker: AFME – “Affluent”), a French clinical-stage medical technology company specializing in the international development and industrialization of innovative implantable medical devices, today announced it has coopted Liane Teplitsky as a new Board member.

Recently appointed CEO of Artedrone, the first autonomous robotic solution for Mechanical Thrombectomy, Liane Teplitsky is a successful seasoned senior executive in the medical device with achievements in building, leading, and growing innovative businesses that elevate the standard of patient care.

With an extensive background in R&D and a passion for advancing intelligent and life-changing medical technologies, Liane has cultivated an expertise in leading business strategy, clinical data development and commercialization for multimillion-dollar global medical technology franchises. Additionally, Liane has demonstrated excellence in building and leading highly functioning, highly engaged teams.

Most recently she was President, Global Robotics, Technology & Data Solutions at Zimmer Biomet where she led the global growth and development of the company’s portfolio of robotics and digital health technologies. Prior to Zimmer Biomet, Liane spent nearly a decade in executive leadership roles at Abbott as Vice President Sales & Division Vice President Marketing for Cardiac Arrhythmia & Heart Failure division and at St Jude Medical, with different strategic roles across multiple product and sales divisions.

Liane holds a Master of Science in Biomedical Engineering from Duke University and a Bachelor of Science in Electrical Engineering and a Bachelor of Science in Physiology from the University of Saskatchewan – Canada.

Sébastien Ladet, Affluent Medical CEO declares: “We are excited to welcome Liane to our board of Directors. Her extensive experience in both the healthcare and technology sectors, combined with her proven track record in leading market development and sales for medical devices, will be invaluable as we continue to advance in the clinical development of our 2 cutting-hedge medical devices to treat mitral valve regurgitation and prepare for their commercialisation.
 

About Affluent Medical

Affluent Medical is a French medical technologies company, founded by Truffle Capital, that aims to become a global leader in the treatment of structural heart diseases, one of the world’s leading causes of mortality, and urinary incontinence, which currently affects one in four adults.

Affluent Medical develops next-generation implants that are minimally invasive, innovative, adjustable and biomimetic, designed to restore essential physiological functions. The candidate products developed by the Company are all undergoing clinical studies in humans.

Subject to raising the funds necessary to finance its strategy and the positive results of ongoing clinical studies, the Company aims to gradually market its products from 2026, directly or indirectly.

For more information, please visit www.affluentmedical.com
 

Contacts:

AFFLUENT MEDICAL
 
Sébastien LADET
Chief Executive Officer
investor@affluentmedical.com
   SEITOSEI.ACTIFIN
   Financial communications / Press relations
   Ghislaine Gasparetto / Jennifer Jullia
   +33 (0)6 21 10 49 24 / +33 (0)1 56 88 11 19
   ghislaine.gasparetto@seitosei-actifin.com /
   jennifer.jullia@seitosei-actifin.com
PRIMATICE
Public Relations France
Thomas ROBOREL de CLIMENS
+33 (0)6 78 12 97 95
thomasdeclimens@primatice.com
   
   MC SERVICES AG

   Media relations Europe
   Maximilian SCHUR / Julia BITTNER
   +49 (0)211 529252 20 / +49 (0)211 529252 28
   affluent@mc-services.eu


25.02.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this